<DOC>
	<DOCNO>NCT01133548</DOCNO>
	<brief_summary>To evaluate pharmacokinetics comparative bioavailability Testosterone absorption 36 Hypogonadal male administration 5 g Testosterone Gel 1.62 % upper arms/shoulders use application site rotation combination application site .</brief_summary>
	<brief_title>Pharmacokinetic Comparative Bioavailability Study Testosterone Absorption After Administration Testosterone Gel 1.62 % Upper Arms/Shoulders Using Application Site Rotation Combination Application Sites Hypogonadal Males</brief_title>
	<detailed_description>To evaluate pharmacokinetics comparative bioavailability Testosterone absorption 36 Hypogonadal male administration 5 g Testosterone Gel 1.62 % upper arms/shoulders use application site rotation combination application site .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria 1 . Hypogonadal males 2 . Screening testosterone &lt; 300 ng/dL Exclusion Criteria 1 . Smokers 2 . Previous history current suspect prostate breast cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>testosterone , hypogonadal , male</keyword>
</DOC>